RetinalGenix Technologies Inc
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. Its products include the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remot… Read more
RetinalGenix Technologies Inc (RTGN) - Total Assets
Latest total assets as of September 2025: $7.00K USD
Based on the latest financial reports, RetinalGenix Technologies Inc (RTGN) holds total assets worth $7.00K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
RetinalGenix Technologies Inc - Total Assets Trend (2020–2024)
This chart illustrates how RetinalGenix Technologies Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
RetinalGenix Technologies Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
RetinalGenix Technologies Inc's total assets of $7.00K consist of 40.6% current assets and 59.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how RetinalGenix Technologies Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: RetinalGenix Technologies Inc's current assets represent 40.6% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 40.6% of total assets in 2024, up from 3.6% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
RetinalGenix Technologies Inc Competitors by Total Assets
Key competitors of RetinalGenix Technologies Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
RetinalGenix Technologies Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - RetinalGenix Technologies Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - RetinalGenix Technologies Inc is currently not profitable relative to its asset base.
RetinalGenix Technologies Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.00 | 0.04 | 0.22 |
| Quick Ratio | 0.00 | 0.04 | 0.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.17 Million | $ -1.86 Million | $ -254.45K |
RetinalGenix Technologies Inc - Advanced Valuation Insights
This section examines the relationship between RetinalGenix Technologies Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 2025.41 |
| Asset Growth Rate (YoY) | 9480.8% |
| Total Assets | $14.95K |
| Market Capitalization | $30.27 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values RetinalGenix Technologies Inc's assets at a significant premium ( 2025.41x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: RetinalGenix Technologies Inc's assets grew by 9480.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for RetinalGenix Technologies Inc (2020–2024)
The table below shows the annual total assets of RetinalGenix Technologies Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $14.95K | +9480.77% |
| 2023-12-31 | $156.00 | -46.94% |
| 2022-12-31 | $294.00 | -94.06% |
| 2021-12-31 | $4.95K | -91.90% |
| 2020-12-31 | $61.08K | -- |